SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025PRNewsWire • 10/17/25
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend YieldsBenzinga • 10/15/25
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?Zacks Investment Research • 10/13/25
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor TypesBusiness Wire • 10/13/25
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren CollaborationPRNewsWire • 10/13/25
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital TherapeuticsBusiness Wire • 10/10/25
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and ConnectionBusiness Wire • 10/10/25
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's DiseaseBusiness Wire • 10/01/25